AstraZeneca Investor Day Presentation Deck
Cardiac and thromboembolic adverse events
Cardiac failure and arterial thromboembolic events were balanced between the two arms
Numerically higher venous thromboembolic events were reported for olaparib + abiraterone
Pulmonary embolism was the most commonly reported venous thromboembolic event
Pulmonary embolism events were mostly incidental findings by CT scans and did not lead to
discontinuation of olaparib or abiraterone
n (%)
Cardiac failure SMQ
Embolic and thrombotic events, arterial SMQ
Embolic and thrombotic events, venous SMQ
Pulmonary embolism
18
CT = computerised tomography; SMQ = Standardised MedDRA Query.
Olaparib + abiraterone
(n=399)
6 (1.5)
8 (2.0)
29
(7.3)
26 (6.5)
Placebo + abiraterone
(n=397)
5 (1.3)
10 (2.5)
13 (3.3)
7 (1.8)
BView entire presentation